colorectal, and 4.5% of other cancer survivors had documented discussions of GUS or SHC. Documented conversations about these topics were more common in patients without evidence of disease (21.8% vs. 5.8%, p < .001). Patients not on active treatment were more likely to have documented discussions than those on active treatment (19.0% vs. 7.9%, p < .001). Patients on targeted therapy were significantly less likely to have documented GUS or SHC conversations with their oncologist (3 5.7% vs. 13.2%, p < .001). Discussion: Women with gynecologic cancers were more likely to have documented GUS or SHC counseling by their oncologist than women with other cancers. Patients without evidence of disease and not receiving treatment were more likely to have documented discussions surrounding these issues. Although only 13.2% of patients had documented GUS or SHC conversations, most of those patients were able to achieve follow-up care, illustrating a large gap in care and revealing an opportunity to address a significant quality of life issue for these patients.
56
Made with FlippingBook Digital Publishing Software